Experienced in Concussion

Dr. Michael J. Mccartney

Internal Medicine

Beth Israel Lahey Health

Medical Care Of Boston Management Corporation

464 Hillside Ave, Suite 304,

Needham, MA

Clinical Trials:Currently Recruiting for 1 Trial

Accepting New Patients

Experienced in Concussion

Beth Israel Lahey Health

Medical Care Of Boston Management Corporation

464 Hillside Ave, Suite 304,

Needham, MA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Mccartney is a primary care provider, practicing in Internal Medicine in Needham, Massachusetts. Dr. Mccartney is rated as an Experienced provider by MediFind in the treatment of Concussion. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Type 2 Diabetes (T2D), and Endoscopy. Dr. Mccartney is currently accepting new patients.

His clinical research consists of participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in MA

Hospital Affiliations

Lahey Hospital & Medical Center, Burlington

Anna Jaques Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

BMC HealthNet

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Commonwealth Care Alliance

MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Horizon Healthcare

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Mass General Brigham Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

Tufts

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 15 Less Insurance Carriers -

Locations

MEDICAL CARE OF BOSTON MANAGEMENT CORPORATION
464 Hillside Ave, Suite 304, Needham, MA 02494

Call: 617-754-0747

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease

Enrollment Status: Recruiting

Publish Date: June 25, 2025

Intervention Type: Drug

Study Drug: Donanemab

Study Phase: Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: September 22, 2025

Intervention Type: Drug

Study Drug: Simufilam

Study Phase: Phase 3

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

Enrollment Status: Completed

Publish Date: August 24, 2025

Intervention Type: Drug

Study Drugs: Tirzepatide, Dulaglutide

Study Phase: Phase 3

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease

Enrollment Status: Completed

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: LY3372689

Study Phase: Phase 2

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Enrollment Status: Completed

Publish Date: July 24, 2025

Intervention Type: Drug

Study Drug: Tirzepatide

Study Phase: Phase 3

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain

Enrollment Status: Completed

Publish Date: July 17, 2024

Intervention Type: Drug

Study Drug: LY3526318

Study Phase: Phase 2

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Enrollment Status: Completed

Publish Date: May 22, 2024

Intervention Type: Other, Drug

Study Drug: Tirzepatide

Study Phase: Phase 3

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain

Enrollment Status: Completed

Publish Date: November 30, 2023

Intervention Type: Drug

Study Drug: LY3016859

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain

Enrollment Status: Completed

Publish Date: November 22, 2023

Intervention Type: Drug

Study Drug: LY3526318

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain

Enrollment Status: Completed

Publish Date: November 14, 2023

Intervention Type: Drug

Study Drug: LY3016859

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis

Enrollment Status: Completed

Publish Date: November 14, 2023

Intervention Type: Drug

Study Drug: LY3016859

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain

Enrollment Status: Completed

Publish Date: November 02, 2023

Intervention Type: Drug

Study Drug: LY3556050

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain

Enrollment Status: Terminated

Publish Date: November 02, 2023

Intervention Type: Drug

Study Drug: LY3556050

Study Phase: Phase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain

Enrollment Status: Completed

Publish Date: November 02, 2023

Intervention Type: Drug

Study Drug: LY3556050

Study Phase: Phase 2

Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain

Enrollment Status: Completed

Publish Date: October 05, 2023

Intervention Type: Drug

Study Drug: LY3526318

Study Phase: Phase 2

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: November 08, 2022

Intervention Type: Drug

Study Drug: BIIB092

Study Phase: Phase 2

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Enrollment Status: Completed

Publish Date: October 13, 2022

Intervention Type: Drug

Study Drug: LY3002813

Study Phase: Phase 2

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Enrollment Status: Completed

Publish Date: February 14, 2022

Intervention Type: Drug

Study Drugs: Tirzepatide, Semaglutide

Study Phase: Phase 3

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: September 02, 2021

Intervention Type: Drug

Study Phase: Phase 3

AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel

Enrollment Status: Completed

Publish Date: September 17, 2020

Intervention Type: Drug

Study Phase: Phase 3

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)

Enrollment Status: Terminated

Publish Date: December 03, 2019

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: October 10, 2019

Intervention Type: Drug

Study Phase: Phase 3

A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy

Enrollment Status: Completed

Publish Date: September 23, 2019

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Enrollment Status: Completed

Publish Date: August 20, 2019

Intervention Type: Drug

Study Phase: Phase 2

View 23 Less Clinical Trials

Similar Doctors

Distinguished in Concussion

Dr. Kevin J. Yeh

Internal Medicine

Distinguished in Concussion

Dr. Kevin J. Yeh

Internal Medicine

Lahey Clinic Inc

1 Essex Ctr Dr,

Peabody, MA

(22.6 miles away)

978-538-4000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Kevin Yeh is a primary care provider, practicing in Internal Medicine in Peabody, Massachusetts. Dr. Yeh is rated as a Distinguished provider by MediFind in the treatment of Concussion. His top areas of expertise are Concussion, Eunuchoidism Familial Hypogonadotropic, Male Pseudohermaphroditism with Gynecomastia, and Wallerian Degeneration.

Experienced in Concussion

Dr. Anna A. Manatis

Internal Medicine

Experienced in Concussion

Dr. Anna A. Manatis

Internal Medicine

Harbor Medical Associates Inc

795 Bridge St,

North Weymouth, MA

(15.7 miles away)

781-337-4105

Languages Spoken:

English

See accepted insurances

Anna Manatis is a primary care provider, practicing in Internal Medicine in North Weymouth, Massachusetts. Dr. Manatis is rated as an Advanced provider by MediFind in the treatment of Concussion. Her top areas of expertise are Chronic Cough, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Hypertension, and Glucocorticoid-Remediable Aldosteronism.

Experienced in Concussion

Dr. Francis J. Wang

Internal Medicine

Experienced in Concussion

Dr. Francis J. Wang

Internal Medicine

20 William St Ste 115,

Wellesley, MA

(2.4 miles away)

781-226-2310

Languages Spoken:

English

See accepted insurances

Francis Wang is a primary care provider, practicing in Internal Medicine in Wellesley, Massachusetts. Dr. Wang is rated as an Experienced provider by MediFind in the treatment of Concussion. His top areas of expertise are Concussion, Ocular Hypertension (OHT), Primary Orthostatic Tremor, and Hypertension.

VIEW MORE CONCUSSION DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccartney's expertise for a condition

ConditionClose